Galeterone and VNPT55 disrupt Mnk-eIF4E to inhibit prostate cancer cell migration and invasion

Metastatic castration-resistant prostate cancer (mCRPC) accounts for a high percentage of prostate cancer mortality. The proprietary compound galeterone (gal) was designed to inhibit proliferation of androgen/androgen receptor (AR)-dependent prostate cancer cell in vitro and in vivo and is currently...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:FEBS J
Egile Nagusiak: Kwegyir-Afful, Andrew K., Bruno, Robert D., Purushottamachar, Puranik, Murigi, Francis N., Njar, Vincent C. O.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2016
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5118139/
https://ncbi.nlm.nih.gov/pubmed/27618366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/febs.13895
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak